HRD scores were comparable between BRCA1-and BRCA2-mutated ovarian cancer but significantly higher than in patients with non-BRCA HRR-related pathogenic mutations (P < 0.001; Fig. S2E) or wild-type HRR-related genes (P < 0.001). The gene discussed is BRCA1; the disease is ovarian cancer.